CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies
This is a open-label, phase 2 study to evaluate the efficacy, safety and PK of CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive hematological malignancies.
Hematological Malignancies
DRUG: Anti-CD7 CAR-T
Overall Response Rate(ORR), Number of patients who achieved response after treatment of CD7 CAR-T cell., 1 Year
Duration of overall response (DOR), Duration of overall response will be assessed from the CAR-T cell infusion to progression, death or last follow-up., 1 Year|Overall survival(OS), OS will be assessed from the CAR-T cell infusion to death or last follow-up., 1 Year
This is a open-label, phase 2 study to evaluate the efficacy, safety and PK of CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive hematological malignancies.